GlassScriptPhysician profile
Timothy Ryan Gloyd
NPI 1760725204
$17,384.07
in general payments reported to CMS, 2019-2025
73 companies · $3,337 in 2025
The $3,337 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $658 · 2021: $2,828 · 2022: $3,791 · 2023: $3,569 · 2024: $2,715 · 2025: $3,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,596 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,595.68 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,402.81 | 2020-2025 | |
| Novo Nordisk INC | $1,549.56 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,238.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,156.70 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $853.62 | 2021-2025 | Biktarvy |
| Glaxosmithkline, LLC. | $820.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $779.56 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $687.87 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $652.45 | 2020-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $646.67 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $580.48 | 2020-2025 | Pifeltro, Delstrigo, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.26 | 2020-2025 | Jardiance |
| Abbott Laboratories | $547.38 | 2021-2025 | Freestyle Libre 3, Gallant, Proclaim |
| Viiv Healthcare Company | $428.74 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Medtronic, INC. | $416.07 | 2021-2025 | Micra, Intellis Adaptivestim, Inceptiv |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.